BPC-157 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
== Pharmacokinetics == AM404 is found in the brains of animals and cerebrospinal fluid of humans taking paracetamol. It is produced from 4-aminophenol by the action of FAAH. It is also generated in vitro from 4-aminophenol by peripheral sensory neurons.
== Services == Pilot is a technology platform for men. It provides telehealth services for men's issues including weight management, erectile dysfunction, premature ejaculation, herpes, skin and hair loss. Pilot prescribes Viagra and is also one of the larger online providers of finasteride in Australia. They also prescribe glucagon-like peptide-1 (GLP-1) receptor agonist medications, including Wegovy (semaglutide) and Mounjaro (tirzepatide), as part of their weight management program, alongside online coaching and diet plans. In Australia, Pilot cannot publicly advertise any medicines by name before consultation, due to advertising restrictions enforced by the Therapeutic Goods Administration (TGA).
ATPases (EC 3.6.1.3, Adenosine 5'-TriPhosphatase, adenylpyrophosphatase, ATP monophosphatase, triphosphatase, ATP hydrolase, adenosine triphosphatase) are a class of enzymes that catalyze the decomposition of ATP into ADP and a free phosphate ion or the inverse reaction. This dephosphorylation reaction releases energy, which the enzyme (in most cases) harnesses to drive other chemical reactions that would not otherwise occur. This process is widely used in all known forms of life. Some such enzymes are integral membrane proteins (anchored within biological membranes), and move solutes across the membrane, typically against their concentration gradient. These are called transmembrane ATPases.
=== EC 1.3.99 With unknown physiological acceptors === EC 1.3.99.1: The activity is included in EC 1.3.5.1, succinate dehydrogenase (quinone) EC 1.3.99.2: Now EC 1.3.8.1, butyryl-CoA dehydrogenase. EC 1.3.99.3: now EC 1.3.8.7, medium-chain acyl-CoA dehydrogenase, EC 1.3.8.8, long-chain acyl-CoA dehydrogenase and EC 1.3.8.9, very-long-chain acyl-CoA dehydrogenase EC 1.3.99.4: 3-oxosteroid 1-dehydrogenase EC 1.3.99.5: 3-oxo-5α-steroid 4-dehydrogenase (acceptor) EC 1.3.99.6: 3-oxo-5β-steroid 4-dehydrogenase EC 1.3.99.7: Now EC 1.3.8.6, glutaryl-CoA dehydrogenase EC 1.3.99.8: 2-furoyl-CoA dehydrogenase EC 1.3.99.9: Now EC 1.21.99.1, β-cyclopiazonate dehydrogenase EC 1.3.99.10: Now EC 1.3.8.4, isovaleryl-CoA dehydrogenase EC 1.3.99.11: transferred to EC 1.3.5.2, dihydroorotate dehydrogenase EC 1.3.99.12: Now classified as EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.99.13: Now EC 1.3.8.8, long-chain-acyl-CoA dehydrogenase EC 1.3.99.14: cyclohexanone dehydrogenase EC 1.3.99.15: Now EC 1.3.7.8 EC 1.3.99.16: isoquinoline 1-oxidoreductase EC 1.3.99.17: quinoline 2-oxidoreductase EC 1.3.99.18: quinaldate 4-oxidoreductase EC 1.3.99.19: quinoline-4-carboxylate 2-oxidoreductase EC 1.3.99.20: Now EC 1.3.7.9, 4-hydroxybenzoyl-CoA reductase EC 1.3.99.21: Now EC 1.3.8.3, (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.99.22: Now EC 1.3.98.3, coproporphyrinogen dehydrogenase EC 1.3.99.23: all-trans-retinol 13,14-reductase EC 1.3.99.24: Now EC 1.3.8.16, 2-amino-4-deoxychorismate dehydrogenase EC 1.3.99.25: carvone reductase EC 1.3.99.26: all-trans-ζ-carotene desaturase EC 1.3.99.27: 1-hydroxycarotenoid 3,4-desaturase EC 1.3.99.28: phytoene desaturase (neurosporene-forming) EC 1.3.99.29: phytoene desaturase (zeta-carotene-forming) EC 1.3.99.30: phytoene desaturase (3,4-didehydrolycopene-forming) EC 1.3.99.31: phytoene desaturase (lycopene-forming) EC 1.3.99.32: glutaryl-CoA dehydrogenase (non-decarboxylating) EC 1.3.99.33: urocanate reductase EC 1.3.99.34: Now classified as EC 1.3.7.11, 2,3-bis-O-geranylgeranyl-sn-glycero-phospholipid reductase EC 1.3.99.35: Now EC 1.3.7.15, chlorophyllide a reductase * EC 1.3.99.36: cypemycin cysteine dehydrogenase (decarboxylating) EC 1.3.99.37: 1-hydroxy-2-isopentenylcarotenoid 3,4-desaturase EC 1.3.99.38: menaquinone-9 β-reductase EC 1.3.99.39: carotenoid φ-ring synthase EC 1.3.99.40: carotenoid χ-ring synthase
Sources: en.wikipedia.org
== Phases == The course of the action potential can be divided into five parts: the rising phase, the peak phase, the falling phase, the undershoot phase, and the refractory period. During the rising phase the membrane potential depolarizes (becomes more positive). The point at which depolarization stops is called the peak phase. At this stage, the membrane potential reaches a maximum. Subsequent to this, there is a falling phase. During this stage the membrane potential becomes more negative, returning towards resting potential. The undershoot, or afterhyperpolarization, phase is the period during which the membrane potential temporarily becomes more negatively charged than when at rest (hyperpolarized). Finally, the time during which a subsequent action potential is impossible or difficult to fire is called the refractory period, which may overlap with the other phases. The course of the action potential is determined by two coupled effects. First, voltage-sensitive ion channels open and close in response to changes in the membrane voltage Vm. This changes the membrane's permeability to those ions. Second, according to the Goldman equation, this change in permeability changes the equilibrium potential Em, and, thus, the membrane voltage Vm. Thus, the membrane potential affects the permeability, which then further affects the membrane potential. This sets up the possibility for positive feedback, which is a key part of the rising phase of the action potential.
Some non-α-amino acids exist in organisms. In these structures, the amine group is displaced further from the carboxylic acid end of the amino acid molecule. Thus a β-amino acid has the amine group bonded to the second carbon away, and a γ-amino acid has it on the third. Examples include β-alanine, GABA, and δ-aminolevulinic acid.
Observe the value of the friction factor for laminar flow at a Reynolds number of 1000. If the value of the friction factor is 0.064, then the Darcy friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.064 are the numerator in the formula for the laminar Darcy friction factor: fD = 64/Re. If the value of the friction factor is 0.016, then the Fanning friction factor is plotted in the Moody diagram. Note that the nonzero digits in 0.016 are the numerator in the formula for the laminar Fanning friction factor: f = 16/Re. The procedure above is similar for any available Reynolds number that is an integer power of ten. It is not necessary to remember the value 1000 for this procedure—only that an integer power of ten is of interest for this purpose.
== Sources == The burning of fossil fuels for energy produces 36.8 billion tonnes of CO2 per year as of 2023. Nearly all of this goes into the atmosphere, where approximately half is subsequently absorbed into natural carbon sinks. Less than 1% of CO2 produced annually is put to commercial use.
Because women diagnosed with Gestational Diabetes (GDM) during pregnancy are at an increased risk for developing Type 2 Diabetes Mellitus after pregnancy, post-pregnancy glucose tolerance testing is needed. Based on the recent meta-analysis conducted by the Patient-Centered Outcomes Research Institute, research has shown that post pregnancy testing reminders are associated with greater adherence to oral glucose tolerance testing up to 1 year postpartum.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.